- Develop long-term relationships of trust with external partners
- Learn how decentralized testing can improve diverse representation in clinical trials
- Gain greater awareness of the importance of diversity, equity and inclusion across the biopharma industry
- Learn to build better patient outcomes through collaborative networks in clinical testing
- Understand the impact of the Clinical Treatment Act on representative patient populations
Diversity in Clinical Trials Summit Underscores Need for Targeting More Broadly Representative Patient Populations
The Diversity in Clinical Trials Summit presented by Dynamic Global Events (“DGE”) in June is an unequaled venue for your team to establish strategies ensuring that a diversity of patient populations are represented in the testing of new drug products.
A key element of conducting sound trials is ensuring that minority populations are included in the testing because they will comprise a portion of the affected patient profile, and may have unique responses to the trials. But historically, clinical trials have excluded and overlooked them.
The Diversity in Clinical Trials Summit aims to re-center drug development around patient diversity in order to improve health outcomes through equitable approaches
Key takeaways:
